Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Four glucagon-like peptide-1 (GLP-1) receptor agonists have been known to reduce the risk of adverse cardiovascular events in type 2 diabetic patients but the...
Four glucagon-like peptide-1 (GLP-1) receptor agonists have been known to reduce the risk of adverse cardiovascular events in type 2 diabetic patients but the...
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide is under development for the treatment of type 2 diabetes. There is...
Several variants of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) have been reported in India from the start of the pandemic. Pragya D....
Due to cardiac remodeling and kidney complications, atrial fibrillation or flutter (AFF) risk is high in patients with chronic kidney disease (CKD) and type...